NASDAQ:INKT - US6036932019 - Common Stock
The current stock price of INKT is 14.24 USD. In the past month the price decreased by -3.26%. In the past year, price increased by 75.8%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 19.87 | 371.68B | ||
AMGN | AMGEN INC | 13.19 | 154.89B | ||
GILD | GILEAD SCIENCES INC | 14.6 | 140.17B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 23.08 | 100.25B | ||
REGN | REGENERON PHARMACEUTICALS | 12.72 | 61.55B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 58.53B | ||
ARGX | ARGENX SE - ADR | 76.83 | 43.59B | ||
ONC | BEONE MEDICINES LTD-ADR | 6.16 | 36.38B | ||
INSM | INSMED INC | N/A | 28.77B | ||
BNTX | BIONTECH SE-ADR | N/A | 24.04B | ||
NTRA | NATERA INC | N/A | 23.09B | ||
BIIB | BIOGEN INC | 8.26 | 19.38B |
MiNK Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, development, and commercialization of allogeneic invariant natural killer T cell therapies to treat cancer and other immune mediated diseases. The company is headquartered in New York City, New York and currently employs 23 full-time employees. The company went IPO on 2021-10-15. The firm is engaged in the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery. Its advanced product candidate, agenT-797, is an off-the-shelf, allogeneic, native iNKT cell therapy designed to provide transformative treatment options. AgenT-797 is an iNKT cell therapy that harnesses the dual power of innate and adaptive immunity. In addition, it is advancing a pipeline of allogeneic, engineered iNKT programs. Its two advanced preclinical engineered programs are MiNK-413, an IL-15 armored CAR-iNKT program targeting B cell maturation antigen (BCMA), and MiNK-215, an IL-15 armored tumor stromal targeting FAP-CAR-iNKT program.
MINK THERAPEUTICS INC
149 Fifth Avenue, Suite 500
New York City NEW YORK US
Employees: 23
Phone: 12129948250
The current stock price of INKT is 14.24 USD. The price decreased by -3.91% in the last trading session.
The exchange symbol of MINK THERAPEUTICS INC is INKT and it is listed on the Nasdaq exchange.
INKT stock is listed on the Nasdaq exchange.
9 analysts have analysed INKT and the average price target is 39.78 USD. This implies a price increase of 179.35% is expected in the next year compared to the current price of 14.24. Check the MINK THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
MINK THERAPEUTICS INC (INKT) has a market capitalization of 64.36M USD. This makes INKT a Micro Cap stock.
MINK THERAPEUTICS INC (INKT) currently has 23 employees.
MINK THERAPEUTICS INC (INKT) has a support level at 14.23 and a resistance level at 15.99. Check the full technical report for a detailed analysis of INKT support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
INKT does not pay a dividend.
MINK THERAPEUTICS INC (INKT) will report earnings on 2025-11-12, before the market open.
MINK THERAPEUTICS INC (INKT) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.88).
The outstanding short interest for MINK THERAPEUTICS INC (INKT) is 3.47% of its float. Check the ownership tab for more information on the INKT short interest.
ChartMill assigns a technical rating of 7 / 10 to INKT. When comparing the yearly performance of all stocks, INKT is one of the better performing stocks in the market, outperforming 96.14% of all stocks.
Over the last trailing twelve months INKT reported a non-GAAP Earnings per Share(EPS) of -2.88. The EPS increased by 41.22% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -453.8% | ||
ROE | N/A | ||
Debt/Equity | N/A |
9 analysts have analysed INKT and the average price target is 39.78 USD. This implies a price increase of 179.35% is expected in the next year compared to the current price of 14.24.